Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

NCT02955589 is registered in ClinicalTrials.gov with HUYABIO International, LLC. as lead sponsor.

NCT NCT02955589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02955589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Lead sponsor
HUYABIO International, LLC.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
November 30, 2019
Enrollment
23 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

adult t-cell lymphoma (atl)